RxDoctor Payments Data

Dionne Hinds, MD

Family Medicine · Port Saint Lucie, FLNPI 1154593184

Payments from drug & device makers

$2,451in general payments, 2019–2025

Across 105 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$594
  • Lilly USA, LLC$475
  • GSK$441
  • Amgen$237
  • AbbVie$194
  • Evoke Pharma, Inc.$125
  • plus $384 from 12 others

What the payments were for

  • Food & beverage$2,451100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,451 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$110,743
Medicare patients
65
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$58,044
XareltoRivaroxaban28$20,178
KerendiaFinerenone15$14,867
FarxigaDapagliflozin Propanediol12$7,834
Rosuvastatin Calcium201$3,905
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,329
LantusInsulin Glargine,hum.Rec.Anlog26$2,269
Aripiprazole18$1,420
Ezetimibe26$1,365
SynthroidLevothyroxine Sodium13$1,323
Humalog Kwikpen U-100Insulin Lispro11$1,231
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$1,129
Fenofibrate53$1,111
Amlodipine Besylate69$840
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$594$58,04455 claims
BayerKerendia$33$14,86715 claims
AstraZenecaFarxiga$32$7,83412 claims
AbbVieSynthroid$194$1,32313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Port Saint Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →